Table 1 Baseline patient demographics and clinical characteristics
|  | Patients treated with SOF/VEL, 12 weeks (n = 9) | Patients treated with SOF/DCV (n = 32) | P value | |
|---|---|---|---|---|
24 weeks (n = 12) | 12 weeks (n = 20) | |||
Mean age (years) | 37.44 ± 9.51 | 49.17 ± 9.10 | 39.35 ± 9.64 | 0.021 |
Sex | Â | Â | Â | 0.458 |
 Male, n (%) | 7 (77.8) | 11 (91.7) | 15 (75) |  |
 Female, n (%) | 2 (22.2) | 1 (8.3) | 5 (25) |  |
History of drug abuse | Â | Â | Â | 0.907 |
 Yes, n (%) | 6 (66.7) | 7 (58.3) | 13(65) |  |
 No, n (%) | 3 (33.3) | 5 (41.7) | 7 (35) |  |
Cirrhosis status | Â | Â | Â | 0.041 |
 Without cirrhosis, n (%) | 7 (78) | 6(50) | 18(90) |  |
 With compensated cirrhosis, n(%) | 2 (22) | 6 (50) | 2 (10) |  |
Renal impairment | Â | Â | Â | 0.258 |
 Yes, n (%) | 0 | 2 (16.7) | 1 (5) |  |
 No, n (%) | 9 (100) | 10 (83.3) | 19 (95) |  |
Previously treated, n (%) | Â | Â | Â | 0.414 |
 Yes, n (%) | 1 (11.1) | 0 (0) | 1 (5) |  |
 No, n (%) | 8 (88.9) | 12 (100) | 19 (95) |  |
Baseline HCV RNA (IU/mL)* | 6.02 ± 1.08 | 5.64 ± 1.74 | 6.18 ± 1.12 | 0.840 |
Platelet (× 109/L) | 157 ± 61.23 | 102.2 ± 32.11 | 164 ± 76.57 | 0.321 |
Albumin (g/L) | 43.05 ± 2.92 | 39.36 ± 7.22 | 39.62 ± 6.68 | 0.871 |
ALT (IU/L) | 193.06 ± 174.35 | 46.82 ± 22.07 | 83.60 ± 82.91 | 0.082 |
AST (IU/L) | 70.89 ± 47.99 | 102.20 ± 32.11 | 69.74 ± 71.22 | 0.647 |
Total bilirrubin (μmol/L) | 11.08 ± 6.99 | 11.38 ± 1.99 | 38.21 ± 66.51 | 0.585 |